Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Gridelli, Cesare;de Marinis, Filippo;Pujol, Jean-Louis;Reck, Martin;Paz-Ares, Luis G.;et.al.
(2012) Journal of Thoracic Oncology — Vol. 7, n° 11, p. 1713-1721 (2012)

Files

pdf1.pdf
  • Restricted Access
  • Adobe PDF
  • 3.03 MB
Request a copy

Details

Authors
  • Gridelli, Cesare
    Author
  • de Marinis, Filippo
    Author
  • Pujol, Jean-Louis
    Author
  • Reck, Martin
    Author
  • Pieters, ThierryUCLouvain
    Author
  • Paz-Ares, Luis G.
    Author
Show more
Abstract
Long-term use of continuation maintenance pemetrexed was well tolerated; resource use was low, corresponding with known pemetrexed toxicities. The EQ-5D results demonstrate that patients tolerate long-term maintenance pemetrexed without worsening QoL.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Gridelli, C., de Marinis, F., Pujol, J.-L., Reck, M., Ramlau, R., Parente, B., Pieters, T., Middleton, G., Corral, J., Winfree, K., Melemed, S., Zimmermann, A., John, W., Beyrer, J., Chouaki, N., Visseren-Grul, C., & Paz-Ares, L. G. (2012). Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Journal of Thoracic Oncology, 7(11), 1713-1721. https://doi.org/10.1097/JTO.0b013e318267cf84 (Original work published 2012)